Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ac-Phe-Arg-Trp-Gly-NH2 is a synthetic tetrapeptide fragment corresponding to the amino acids 7 through 10 of alpha-melanocyte-stimulating hormone (alpha-MSH). It is primarily used as a pharmacological tool to investigate the structure-activity relationships of the melanocortin system. The peptide demonstrates significant interspecies variability in its activity at the melanocortin 1 receptor (MC1R); while it acts as an alpha-MSH antagonist in the lizard *Anolis carolinensis*, it is ineffective in certain amphibians and fish. In murine melanoma models, the fragment does not display intrinsic agonist or antagonist activity but significantly potentiates alpha-MSH-induced tyrosinase activity, suggesting it may act as a facilitator or positive allosteric modulator of the receptor complex.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ac-Phe-Arg-Trp-Gly-NH2.